D Cavan1, L Makaroff2, J da Rocha Fernandes3, M Sylvanowicz4, P Ackland5, J Conlon6, D Chaney7, A Malhi8, J Barratt9. 1. International Diabetes Federation, Chaussée de la Hulpe 166, Brussels, Belgium. Electronic address: davidcavan@hotmail.com. 2. International Diabetes Federation, Chaussée de la Hulpe 166, Brussels, Belgium; Department of Microbiology and Immunology, University of Leuven, Herestraat 49, Leuven, Belgium. Electronic address: lydia.makaroff@kuleuven.be. 3. International Diabetes Federation, Chaussée de la Hulpe 166, Brussels, Belgium. Electronic address: joao.fernandes@idf.org. 4. Bayer AG, Mullerstraße 178, 13353 Berlin, Germany. Electronic address: michelle.sylvanowicz@bayer.com. 5. The International Agency for the Prevention of Blindness, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom. Electronic address: packland@iapb.org. 6. The International Agency for the Prevention of Blindness, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom. Electronic address: jconlon@iapb.org. 7. International Diabetes Federation, Chaussée de la Hulpe 166, Brussels, Belgium; Diabetes UK Northern Ireland, Bridgewood House, Newforge Business Park, Newforge Lane, Belfast, United Kingdom. Electronic address: David.Chaney@diabetes.org.uk. 8. International Diabetes Federation, Chaussée de la Hulpe 166, Brussels, Belgium. Electronic address: Mahli.Amrinder@idf.org. 9. International Federation on Ageing, 351 Christie Street, Toronto, Ontario, Canada. Electronic address: jbarratt@ifa-fiv.org.
Abstract
AIM: To assess the level of awareness, prevention and treatment of Diabetic Eye Disease (DED) comprising Diabetic Retinopathy (DR) and Diabetic Macula Edema (DME) retinopathy among adults with diabetes and health professionals. METHODS: The Diabetic Retinopathy Barometer Study consisted of a qualitative study, which consisted of semi-structured interviews, and a quantitative study using online surveys for adults with diabetes and for health professionals. RESULTS: A total of 4340 adults with diabetes and 2329 health professionals participated in the surveys. Diabetic eye disease (DED) without macular edema (DME) was reported by 19.5% of adults with diabetes and a further 7.6% reported that they had DME. Although 94% of adults with diabetes saw a health care professional for their diabetes, only 79% had ever had an eye examination for DED, and 23% had not had an eye examination in the last year. Moreover, 65% of the ophthalmologists surveyed reported that most patients presented when visual problems had already occurred. Overall, 62% of people with DED had received treatment. Of these, 74% had laser therapy, 29% surgery and 24% anti-VEGF therapy. CONCLUSION: Strategic investment is required to enhance patient education and professional training on the importance of regular eye examinations; and in providing accessible DR screening programmes and proactive treatments.
AIM: To assess the level of awareness, prevention and treatment of Diabetic Eye Disease (DED) comprising Diabetic Retinopathy (DR) and Diabetic Macula Edema (DME) retinopathy among adults with diabetes and health professionals. METHODS: The Diabetic Retinopathy Barometer Study consisted of a qualitative study, which consisted of semi-structured interviews, and a quantitative study using online surveys for adults with diabetes and for health professionals. RESULTS: A total of 4340 adults with diabetes and 2329 health professionals participated in the surveys. Diabetic eye disease (DED) without macular edema (DME) was reported by 19.5% of adults with diabetes and a further 7.6% reported that they had DME. Although 94% of adults with diabetes saw a health care professional for their diabetes, only 79% had ever had an eye examination for DED, and 23% had not had an eye examination in the last year. Moreover, 65% of the ophthalmologists surveyed reported that most patients presented when visual problems had already occurred. Overall, 62% of people with DED had received treatment. Of these, 74% had laser therapy, 29% surgery and 24% anti-VEGF therapy. CONCLUSION: Strategic investment is required to enhance patient education and professional training on the importance of regular eye examinations; and in providing accessible DR screening programmes and proactive treatments.
Authors: Sara Vaz-Pereira; João Paulo Castro-de-Sousa; David Martins; Joaquim Prates Canelas; Pedro Reis; António Sampaio; Helena Urbano; Paulo Kaku; João Nascimento; Carlos Marques-Neves Journal: Ophthalmic Res Date: 2019-12-04 Impact factor: 2.892
Authors: Yong Seok Han; Mythili Pathipati; Carolyn Pan; Loh-Shan Leung; Mark Scott Blumenkranz; David Myung; Brian Chiwing Toy Journal: J Vitreoretin Dis Date: 2020-10-05
Authors: Nyawira Mwangi; Covadonga Bascaran; Mark Ng'ang'a; Jacqueline Ramke; Mathew Kipturgo; Stephen Gichuhi; Min Kim; David Macleod; Consuela Moorman; David Muraguri; Esbon Gakuo; Lawrence Muthami; Allen Foster Journal: Pilot Feasibility Stud Date: 2020-07-16
Authors: Fiona Riordan; Emmy Racine; Eunice T Phillip; Colin Bradley; Fabiana Lorencatto; Mark Murphy; Aileen Murphy; John Browne; Susan M Smith; Patricia M Kearney; Sheena M McHugh Journal: Implement Sci Date: 2020-05-19 Impact factor: 7.327